Four Months Off and Still Not Himself
A 29-year-old competitive bodybuilder, four months off self-administered anabolic steroids, whose own hormone axis hasn't come back on its own — and a debate over whether to help restart it or simply wait it out.
Trent B. has competed in regional bodybuilding shows for six years and self-administered a range of anabolic-androgenic steroids for most of that time, a history he disclosed candidly at this visit after four months of what he describes as feeling genuinely unwell since stopping — profound fatigue, loss of libido, and a depressed mood distinct, he says, from anything he experienced during active use. He stopped after his most recent competition, intending what he calls a clean off-season, and expected to feel normal again within a few weeks. He hasn't.
His labs confirm what his symptoms suggest: testosterone 89 ng/dL, markedly low, with LH and FSH both suppressed rather than elevated — the expected pattern after prolonged exogenous androgen exposure, which shuts down the hypothalamic-pituitary-gonadal axis through the same negative feedback mechanism at work in several other cases in this volume, just at a far greater intensity and duration than typical therapeutic testosterone replacement produces. The central question his case raises is how reliably, and how quickly, that suppressed axis recovers once the exogenous drive stops, and whether anything should be done to help it along versus simply waiting.
The recovery protocols commonly described as post-cycle therapy — typically hCG to directly stimulate testicular Leydig cell function, sometimes combined with clomiphene or tamoxifen to raise endogenous LH and FSH through estrogen-receptor blockade at the hypothalamus — are widely used within the community Trent competes in, but the evidence supporting them is drawn overwhelmingly from that same community's own practice and small case series, not controlled trials specifically testing recovery outcomes after real-world anabolic steroid use. Existing observational data on spontaneous recovery after stopping anabolic steroids is genuinely mixed: many men do recover HPG axis function without intervention, typically within months, but recovery time and completeness appear to track with the total dose and duration of prior use, and some men with long, high-dose histories like Trent's show prolonged or incomplete recovery even a year or more out. What four months cannot settle is which of those two courses he is on; what it does rule out is the quickest one, the few-weeks recovery he walked in expecting.
Clinic visit, deciding whether to help an axis restart itself
Four months of profound, functionally limiting symptoms after six years of use is long enough that I'd rather give his axis an active signal to restart than continue waiting on spontaneous recovery that may or may not fully happen. hCG stimulates his own Leydig cells directly, and clomiphene works upstream at the hypothalamus — together they address different points along the same suppressed axis rather than leaving it to recover entirely on its own timeline.
I want to be honest about where this specific protocol's evidence actually comes from, because I think it changes how confidently we should recommend it. The hCG-plus-clomiphene combination as post-cycle therapy is drawn almost entirely from bodybuilding-community practice and small case series, not controlled trials testing recovery after real anabolic steroid use specifically. Observational data on spontaneous recovery is genuinely mixed — many men do recover on their own within months, and intervening now risks treating a process that may simply still be running its course.
I'm not saying the mechanism is wrong — hCG and clomiphene plausibly could help. I'm saying we don't actually know that they reliably do, in this specific situation, better than time alone would.
There's also the underlying pattern worth naming directly, separate from which recovery approach we pick: six years of unsupervised, self-dosed use is itself the thing most likely to recur if he goes back to competition unsupported. Whatever we do pharmacologically, I want an honest conversation with him about that risk, and a defined recheck point — testosterone, LH, and FSH again in eight weeks — so this doesn't become either treatment or observation extended indefinitely without a decision point.
Agreed: hCG and clomiphene started together as a time-bound trial, with testosterone, LH, and FSH rechecked at eight weeks, alongside a direct conversation about the pattern of unsupervised use underlying this presentation, not just its pharmacologic fix.
Not agreed, and left explicit: whether this intervention will do meaningfully better than the spontaneous recovery observation alone might have produced. The clinical pharmacologist's underlying point — that the evidence for this exact protocol is thinner than its common use suggests — was not overruled, only outweighed for now by the real severity of what Trent is currently living with.